Work Here?
Beeline Medicines
Work Here?
Clinical-stage biotech developing precision autoimmune therapies
Beeline Medicines
Work Here?
Clinical-stage biotech developing precision autoimmune therapies
Overview
Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.
About Beeline Medicines
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series A
Total Funding
$426.3M
Headquarters
Stamford, Connecticut
Founded
2025
Get referred to Beeline Medicines
See people who can refer or advise you
Simplify's Take
What believers are saying
- Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million total.
- Existing investors Bain Capital, CPP Investments, and BMS doubled down before Phase 2 data.
- Management says pivotal lupus preparation has started, signaling confidence in a registrational path.
What critics are saying
- Afimetoran's Phase 2 lupus readout in 2H 2026 is the company's defining binary event.
- Merck KGaA's enpatoran missed the SLE endpoint in 2025, weakening the TLR7/8 thesis.
- If afimetoran disappoints, Beeline's five-asset platform becomes a costly BMS asset recycle.
What makes Beeline Medicines unique
- Beeline launched in April 2026 with five BMS-licensed programs, not discovery-stage science.
- Afimetoran is a once-daily oral TLR7/8 inhibitor, designed for mechanistically precise lupus suppression.
- Saqib Islam built SpringWorks into a $3.9 billion Merck KGaA acquisition in 2025.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$426.3M
Above
Industry Average
Funded Over
1 Rounds
Industry standards
Benefits
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Health Insurance
Company Equity
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -12%1 year growth
↓ -12%2 year growth
↓ -12%Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]
Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.
Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.
Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.
– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases – – Lead...
Beeline Medicines is Hiring for 22 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Beeline Medicines
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series A
Total Funding
$426.3M
Headquarters
Stamford, Connecticut
Founded
2025
Beeline Medicines is Hiring for 22 Jobs on Simplify!
Find jobs on Simplify and start your career today